127408-03-1

Basic information

• Product Name: 4-Bromo-3-fluoro-2-methylaniline
• Synonyms: 4-Bromo-3-fluoro-2-methylaniline;4-Bromo-3-fluoro-2-methyl-phenylamine
• CAS NO: 127408-03-1
• Molecular Formula: C₇H₇BrFN
• Molecular Weight: 204.0395832
• Mol File: 127408-03-1.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 244.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.589±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 2.73±0.10(Predicted)
• CAS DataBase Reference: 4-Bromo-3-fluoro-2-methylaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-3-fluoro-2-methylaniline(127408-03-1)
• EPA Substance Registry System: 4-Bromo-3-fluoro-2-methylaniline(127408-03-1)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 127408-03-1(Hazardous Substances Data)

Usage

General Description

4-Bromo-3-fluoro-2-methylaniline is a chemical compound with the molecular formula C7H7BrFN. It is an organic compound that consists of a benzene ring with a bromine atom, a fluorine atom, and a methyl group attached to it. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is also used as a raw material in the production of dyes and other fine chemicals. 4-Bromo-3-fluoro-2-methylaniline has a variety of industrial applications and is considered an important building block in organic synthesis. However, it is important to handle this compound with caution due to its potential hazards and toxicity.

Upstream product

• 443-86-7 3-fluoro-2-methylaniline 

Downstream Products

• 757247-93-1 4-Amino-2-fluoro-3-methylbenzonitrile 
• 1613505-03-5 4-fluoro-5-(2-trifluoromethylphenyl)-1H-indazole 
• 1082041-85-7 5-bromo-4-fluoro-1H-indazole 

Relevant articles and documents

Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 Diabetes

A novel series of pyridones were discovered as potent EP3 antagonists. Optimization guided by EP3 binding and functional assays as well as by eADME and PK profiling led to multiple compounds with good physical properties, excellent oral bioavailability, and a clean in vitro safety profile. Compound 13 was identified as a lead compound as evidenced by the reversal of sulprostone-induced suppression of glucose-stimulated insulin secretion in INS 1E β-cells in vitro and in a rat ivGTT model in vivo. A glutathione adduction liability was eliminated by replacing the naphthalene of structure 13 with the indazole ring of structure 43.

Compounds and their use in treatment on hepatitis B

The invention provides compounds, a pharmaceutical composition containing the compounds and an application of the compounds. The compound is a compound shown in a formula (I) or a stereoisomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The compound provided by the invention can interfere with the shell assembly process of hepatitis B virus, thereby inhibiting hepatitis B virus replication. Moreover, the compound has good absorption, relatively high biological activity and availability and low toxicity, particularly has relatively strong stability in vivo, is not easy to decompose and has long drug effect time, so that an effect of treating hepatitis B is achieved and the compound has a goodapplication prospect.

Method for synthesizing 5-bromo-4-fluoro-1H-indazole

The invention belongs to the field of organic synthesis, and discloses a method for synthesizing 5-bromo-4-fluoro-1H-indazole. The synthesis method comprises the steps: adopting 3-fluoro-2-methylaniline as a raw material, and performing three steps of rea